The first suggests anti–PD-(L)1 therapies rejuvenate tumor-specific cytotoxic T cells already residing in the tumor microenvironment, leading to their activation, proliferation, and trafficking to micrometastatic deposits. Here, CD274 is linked to neoplasm.